Nano-C Secures EPA Clearance for Fullerene Derivative Production and Distribution

Nano-C, Inc. received approval from the U.S. Environmental Protection Agency (EPA) to manufacture and sell fullerenes and PCBM, a patented fullerene derivative commonly used in Organic Photovoltaic (OPV) and other applications.

Nano-C worked extensively with the EPA through the TSCA Pre-manufacture Notice ("PMN") process to develop effective environmental, health and safety protocols for the production and use of PCBM. This follows PMN clearances that Nano-C received earlier this year for fullerene manufacture.

"We are delighted to have received the EPA's clearance. This makes Nano-C the only approved commercial source for these advanced materials and chemicals in the United States. Having earlier solidified our patent position with an exclusive license for PCBM from Unidym, Inc., EPA clearance for PCBM manufacture and sale is the final step toward its commercial application in OPV and other devices," said Viktor Vejins, President and CEO of Nano-C.

Nano-C worked with Mr. John V. Massingale of Greenwich Chemical Consulting, and Mr. Herb Estreicher and Ms. Martha Marrapese of Keller and Heckman LLP, a Washington DC based regulatory law firm, each leading authorities on TSCA and corresponding law. Reflecting on the process, Mr. Tom Lada, Nano-C's Director of Fullerene Operations said, "We could not have had a better team working with us and the EPA. We were able to address the EPA's concerns throughout the PMN process and have entered into effective Consent Orders with the EPA that provide a sound foundation for Nano-C and its customers."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.